ScoreWhy is Neurocrine Biosciences, Inc. ?
1
High Management Efficiency with a high ROE of 20.73%
2
Company has a low Debt to Equity ratio (avg) at times
3
Healthy long term growth as Net Sales has grown by an annual rate of 22.29% and Operating profit at 14.21%
4
Positive results in Dec 25
- OPERATING CASH FLOW(Y) Highest at USD 782.7 MM
- ROCE(HY) Highest at 16.38%
- RAW MATERIAL COST(Y) Fallen by -0.3% (YoY)
5
With ROE of 14.28%, it has a expensive valuation with a 5.20 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 14.94%, its profits have risen by 2.5% ; the PEG ratio of the company is 10.5
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Neurocrine Biosciences, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Neurocrine Biosciences, Inc. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Neurocrine Biosciences, Inc.
17.13%
-0.10
34.15%
S&P 500
17.78%
0.92
19.35%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
22.29%
EBIT Growth (5y)
14.21%
EBIT to Interest (avg)
16.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.85
Tax Ratio
34.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
30.41%
ROE (avg)
20.73%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
5.20
EV to EBIT
26.23
EV to EBITDA
24.82
EV to Capital Employed
7.40
EV to Sales
5.22
PEG Ratio
10.48
Dividend Yield
NA
ROCE (Latest)
28.21%
ROE (Latest)
14.28%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 782.7 MM
ROCE(HY)
Highest at 16.38%
RAW MATERIAL COST(Y)
Fallen by -0.3% (YoY
CASH AND EQV(HY)
Highest at USD 2,595.2 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -31.02 %
NET SALES(Q)
Highest at USD 805.5 MM
PRE-TAX PROFIT(Q)
At USD 253.7 MM has Grown at 51.46%
NET PROFIT(Q)
At USD 162.88 MM has Grown at 53.36%
-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.82 times
Here's what is working for Neurocrine Biosciences, Inc.
Operating Cash Flow
Highest at USD 782.7 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 805.5 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 805.5 MM has Grown at 28.33%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 253.7 MM has Grown at 51.46%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 162.88 MM has Grown at 53.36%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 2,595.2 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -31.02 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -0.3% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Neurocrine Biosciences, Inc.
Inventory Turnover Ratio
Lowest at 0.82 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
